Literature DB >> 1949788

Cardiomyopathy associated with high-dose interleukin-2 therapy.

A C Beck1, J H Ward, E H Hammond, R B Wray, W E Samlowski.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1949788      PMCID: PMC1002997     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


× No keyword cloud information.
  21 in total

Review 1.  Myocarditis and endomyocardial biopsy in unexplained heart failure: a diagnosis in search of a disease.

Authors:  J T Lie
Journal:  Ann Intern Med       Date:  1988-10-01       Impact factor: 25.391

2.  Myocardial toxic effects during recombinant interleukin-2 therapy.

Authors:  R Nora; J S Abrams; N S Tait; D J Hiponia; H J Silverman
Journal:  J Natl Cancer Inst       Date:  1989-01-04       Impact factor: 13.506

3.  Septic shock. Hemodynamics and pathogenesis.

Authors:  M M Parker; J E Parrillo
Journal:  JAMA       Date:  1983 Dec 23-30       Impact factor: 56.272

4.  The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells.

Authors:  E R Gaynor; L Vitek; L Sticklin; S P Creekmore; M E Ferraro; J X Thomas; S G Fisher; R I Fisher
Journal:  Ann Intern Med       Date:  1988-12-15       Impact factor: 25.391

5.  Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock.

Authors:  F P Ognibene; S A Rosenberg; M Lotze; J Skibber; M M Parker; J H Shelhamer; J E Parrillo
Journal:  Chest       Date:  1988-10       Impact factor: 9.410

6.  Pathologic findings associated with interleukin-2-based immunotherapy for cancer: a postmortem study of 19 patients.

Authors:  A H Kragel; W D Travis; L Feinberg; S Pittaluga; L M Striker; W C Roberts; M T Lotze; J J Yang; S A Rosenberg
Journal:  Hum Pathol       Date:  1990-05       Impact factor: 3.466

7.  Idiopathic cardiomyopathies. A review of pathologic studies and mechanisms of pathogenesis.

Authors:  M B Gravanis; A A Ansari
Journal:  Arch Pathol Lab Med       Date:  1987-10       Impact factor: 5.534

8.  Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.

Authors:  B T Gemlo; M A Palladino; H S Jaffe; T P Espevik; A A Rayner
Journal:  Cancer Res       Date:  1988-10-15       Impact factor: 12.701

9.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

Authors:  S A Rosenberg; M T Lotze; L M Muul; A E Chang; F P Avis; S Leitman; W M Linehan; C N Robertson; R E Lee; J T Rubin
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

Review 10.  Clinical toxicity of interferons in cancer patients: a review.

Authors:  J R Quesada; M Talpaz; A Rios; R Kurzrock; J U Gutterman
Journal:  J Clin Oncol       Date:  1986-02       Impact factor: 44.544

View more
  2 in total

Review 1.  Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.

Authors:  V B Pai; M C Nahata
Journal:  Drug Saf       Date:  2000-04       Impact factor: 5.606

Review 2.  Cardiotoxicity of Systemic Melanoma Treatments.

Authors:  Neha Mukunda; Srilakshmi Vallabhaneni; Benedicte Lefebvre; Michael G Fradley
Journal:  Curr Treat Options Oncol       Date:  2022-02-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.